YUTIQ is administered in the office setting using a specially designed applicator.
To learn about the YUTIQ administration process, you may watch the injection training video or download the brochure.
The administration video is a step-by-step guide to administering YUTIQ, including preparation, insertion procedure, and implant placement.
The YUTIQ implant is inserted into the vitreous cavity via a 25-gauge needle. Each implant contains 0.18 mg fluocinolone acetonide (FAc) and is engineered to provide a submicogram release at an initial rate of 0.25 μg/day lasting 36 months. Each sterile, single-use, preloaded custom applicator is packaged in a sealed tray that should be stored at room temperature between 59oF and 86oF.
After Dr. Singer speaks about the ideal patient, use of YUTIQ, and patient follow-up, he performs a YUTIQ injection on an actual patient in his office.
Dr. Callanan, a uveitis specialist, discusses the use and potential side effects of YUTIQ as well as the ideal patient. An inset of the injection being performed accompanies this video.
Dr. Wang, a uveitis specialist, discusses how he and his team prepared to begin injecting YUTIQ in their office, including support from the company and identifying patients. He then performs the injection on an actual patient.
CONTRAINDICATIONS
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
Please see full Prescribing Information at hcp.yutiq.com/pi/.
This site is intended for US residents only. YUTIQ is a registered trademark of Alimera Sciences, Inc.
CONTINUOUS MICRODOSING and the CONTINUOUS MICRODOSING symbol are trademarks of Alimera Sciences, Inc.
1-844-445-8843. US-YTQ-MMM-0032